Trial Profile
A Phase II Trial of Short-Term Everolimus (RAD001) to Predict Response in Women With Operable Breast Cancer.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 11 Aug 2011 Planned end date changed from Jan 2012 to Jun 2009 as reported by ClinicalTrials.gov.
- 17 Jun 2009 Status changed from active, no longer recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 23 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.